The former head of GlaxoSmithKline’s China division has been accused of bribery. Bloomberg reports that Mark Reilly has been accused of ordering employees to bribe doctors, hospitals and medical groups to boost drug sales.

GSK told Bloomberg that they cooperating with authorities. The drugmaker noted earlier this year that corruption allegations have inflicted damage on regional sales.